Crism Therapeutics: Director Dealing

CRISM Therapeutics

07/04/2025 11:46

RNS Number : 9432D

CRISM Therapeutics Corporation

07 April 2025

 

7 April 2025

 

CRISM Therapeutics Corporation

(AIM:CRTX)

 

Director Dealing

 

CRISM Therapeutics Corporation ("CRISM" or the "Company") announces that it has been notified that Non-Executive Director, Gerald Beaney has purchased 20,182 ordinary shares of the Company at a price of 9.88 pence per share.

 

Following this purchase, Mr Beaney holds 45,182 ordinary shares, which represents approximately 0.14% of the Company's total issued share capital of 32,678,312.

 

 

Enquiries:

 

Company
Nomad and Broker
Financial PR
CRISM Therapeutics Corporation
S.P. Angel Corporate Finance LLP
Buchanan
Andrew Webb, CEO
Chris McConville, CSO
Richard Morrison
Adam Cowl
Mark Court mark.court@buchanancomms.co.uk
Jamie Hooper jamie.hooper@buchanancomms.co.uk
via Buchanan
+44 (0) 20 3470 0470
+44 (0) 20 7466 5000

 

 

 

Dealings by Persons Discharging Managerial Responsibilities

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Gerald Beaney
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
CRISM Therapeutics Corporation
b)
LEI
213800XFW6MKVCHHPW88
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares with no par value
Identification code
ISIN: VGG042401262
b)
Nature of the transaction
Purchase of shares
c)
Price(s) and volume(s)
Director/PDMR
Price
Volume
Gerald Beaney
9.88
20,182
d)
Aggregated information
- Aggregated volume
20,182
- Price
£1,993.98
e)
Date of the transaction
7 April 2025
f)
Place of the transaction
Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHFLFVISRIDIIE